Fresenius Medical Care Sees US Plans for Kidney Disease as Positive
As a health professional, you need the leading dialysis products, renal pharmaceuticals and critical care solutions. Let's work together to find you the tools you need, so you can deliver the best care for patients.
Power your practice with our resources. We're here to help support your patients and your thriving practice.
Every day, we’re working tirelessly to transform the future of healthcare. Because every patient deserves treatment as strong as they are.
Browser Upgrade Recommended: Our website has detected that you are using a version of Internet Explorer that will prevent you from accessing certain features on FMCNA.com. We strongly recommend that you use a different browser to optimize your viewing experience. Supported browsers include Chrome, Edge, Firefox, and Safari.
Waltham, Mass., Aug. 2, 2018 – Frenova Renal Research, a division of Fresenius Medical Care North America (FMCNA) and the world’s only contract clinical research services provider dedicated exclusively to renal research, today announces the addition of a fifth clinical research site to its Site Management Organization (SMO). The new site in Baton Rouge, La., brings 6,000 chronic kidney disease (CKD) patients and 1,500
The new site is led by Principal Investigator Michael W. Roppolo, M.D., of Renal Associates of Baton Rouge, L.L.C. Frenova will oversee all operational trial activities, including the training and management of Frenova’s clinical research staff working at the site. In addition, Frenova will manage research site protocol adherence, data quality, site payment, regulatory obligations to the FDA and IRB, drug accountability and site performance.
The Baton Rouge site also joins the F1RST Up (Frenova Rapid
“This important collaboration will bring more patients into our network who are eligible for renal-specific clinical studies, enabling us to support the increasing number of clinical trials seeking to improve the lives of people with renal disease,” said Kurt Mussina, vice president, general manager, Frenova Renal Research.
“It is a privilege to be part of Frenova’s growing Site Management Organization,” said Michael Roppolo, MD, Partner, Renal Associates of Baton Rouge, L.L.C. “Frenova SMO and the F1RST Up network are improving the health outcomes and quality of life for patients through important clinical research. By allowing Frenova to direct the clinical research staff and trial operations, we can enroll more patients into studies and ultimately help patients by introducing new advances and treatments to the market.”
To learn more about Frenova Renal Research’s clinical trial initiation program, read, “F1RST Up®: Accelerating Clinical Trial Start-Up” in Fresenius Medical Care North America’s 2018 Annual Medical Report.
Frenova is the world’s only drug and medical device contract clinical development services provider dedicated exclusively to renal research and its adjacent conditions. As a Fresenius Medical Care North America company, Frenova manages a networked system of clinical research assets and resources including over 450 principal investigators at more than 260 sites representing 160 medical practices and nearly 700 dialysis clinics. Frenova manages clinical trials in kidney disease and its adjacent medical conditions. Visit www.FrenovaRenalResearch.com for more information.
Fresenius Medical Care North America is the premier health care company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs and urgent care centers, Fresenius Medical Care North America